Palisade Bio (PALI) closed at $1.25 on November 4, 2026, up 1.6% from the previous close, on volume of 1,916,825 shares (30-day average 3,705,030).
Data as of November 4, 2026.
Globe Newswire (Wed, 28-Oct 8:32 AM ET)
Globe Newswire (Tue, 20-Oct 8:05 AM ET)
Globe Newswire (Mon, 12-Oct 8:05 AM ET)
Globe Newswire (Mon, 28-Sep 8:50 AM ET)
Palisade Bio Expands Global Phase 2b ASCENTRA-UC Program with Health Canada CTA Clearance
Globe Newswire (Wed, 23-Sep 8:45 AM ET)
Globe Newswire (Tue, 22-Sep 8:35 AM ET)
Palisade Bio to Present at Stifel 2026 Virtual Immunology and Inflammation Forum
Globe Newswire (Mon, 21-Sep 9:00 AM ET)
Palisade Bio to Participate in Upcoming Investor Conferences
Globe Newswire (Thu, 3-Sep 9:00 AM ET)
Globe Newswire (Mon, 10-Aug 4:20 PM ET)
Market Chameleon (Mon, 29-Jun 7:10 AM ET)
Palisade Bio Inc is a clinical-stage biopharma company focused on identifying and developing therapeutics that protect the integrity of the intestinal barrier. Its portfolio consists of a PALI-2108 for the treatment of IBD, including UC and CD, and is researching PALI-1908.
Palisade Bio trades on the NASDAQ stock market under the symbol PALI.
As of November 4, 2026, PALI stock price climbed to $1.25 with 1,916,825 million shares trading.
PALI has a beta of 1.22, meaning it tends to be more sensitive to market movements. PALI has a correlation of 0.03 to the broad based SPY ETF.
PALI has a market cap of $217.84 million. This is considered a Small Cap stock.
In the last 3 years, PALI traded as high as $22.35 and as low as $.53.
The top ETF exchange traded funds that PALI belongs to (by Net Assets): VTI, IWM, VXF, IWN, VTWO.
PALI has underperformed the market in the last year with a price return of -37.5% while the SPY ETF gained +13.3%. PALI has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -35.6% and -12.6%, respectively, while the SPY returned +1.5% and -0.3%, respectively.
PALI support price is $1.16 and resistance is $1.30 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that PALI shares will trade within this expected range on the day.
